GlassScriptPhysician profile
Nikole Czapp
NPI 1407385966
$971.87
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $253 · 2021: $577 · 2022: $141.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $198.97 | 2020-2021 | |
| Pfizer INC. | $161.16 | 2020-2021 | |
| Glaxosmithkline, LLC. | $144.35 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $77.25 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.43 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.76 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.08 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $44.92 | 2020 | |
| Abbott Laboratories | $36.06 | 2021 | |
| Novo Nordisk INC | $32.24 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.78 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.37 | 2021 | |
| Esperion Therapeutics, INC. | $18.16 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikole Czapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.